Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Copenhagen, Denmark, 23 April 2025 – Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new...
-
Copenhagen, Denmark, 23 April 2025 – Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new...
-
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First subjects dosed in double-blind, placebo-controlled...